Select Publications

Journal articles

Knox MC; Ni J; Bece A; Bucci J; Chin Y; Graham PH; Li Y, 2020, 'A Clinician's Guide to Cancer-Derived Exosomes: Immune Interactions and Therapeutic Implications', Frontiers in Immunology, vol. 11, http://dx.doi.org/10.3389/fimmu.2020.01612

Ni J; Cheung BB; Beretov J; Duan W; Bucci J; Malouf D; Graham P; Li Y, 2020, 'CD44 variant 6 is associated with prostate cancer growth and chemo-/radiotherapy response in vivo', Experimental Cell Research, vol. 388, pp. 111850 - 111850, http://dx.doi.org/10.1016/j.yexcr.2020.111850

Wang J; Ni J; Beretov J; Thompson J; Graham P; Li Y, 2020, 'Exosomal microRNAs as liquid biopsy biomarkers in prostate cancer', Critical Reviews in Oncology/Hematology, vol. 145, pp. 102860 - 102860, http://dx.doi.org/10.1016/j.critrevonc.2019.102860

Pang B; Zhu Y; Ni J; Thompson J; Malouf D; Bucci J; Graham P; Li Y, 2020, 'Extracellular vesicles: The next generation of biomarkers for liquid biopsy-based prostate cancer diagnosis', Theranostics, vol. 10, pp. 2309 - 2326, http://dx.doi.org/10.7150/thno.39486

Tsao T; Beretov J; Ni J; Bai X; Bucci J; Graham P; Li Y, 2019, 'Cancer stem cells in prostate cancer radioresistance', Cancer Letters, vol. 465, pp. 94 - 104, http://dx.doi.org/10.1016/j.canlet.2019.08.020

Ni J; Bucci J; Malouf D; Knox M; Graham P; Li Y, 2019, 'Exosomes in Cancer Radioresistance', Frontiers in Oncology, vol. 9, http://dx.doi.org/10.3389/fonc.2019.00869

Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y, 2019, 'Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression', BMC Cancer, vol. 19, http://dx.doi.org/10.1186/s12885-019-5824-9

Feng X; Bai X; Ni J; Wasinger VC; Beretov J; Zhu Y; Graham P; Li Y, 2019, 'CHTOP in chemoresistant epithelial ovarian cancer: A novel and potential therapeutic target', Frontiers in Oncology, vol. 9, http://dx.doi.org/10.3389/fonc.2019.00557

Ni J; Bongers A; Chamoli U; Bucci J; Graham P; Li Y, 2019, 'In Vivo 3D MRI Measurement of Tumour Volume in an Orthotopic Mouse Model of Prostate Cancer', Cancer Control, vol. 26, pp. 1073274819846590, http://dx.doi.org/10.1177/1073274819846590

Chang L; Ni J; Zhu Y; Pang B; Graham P; Zhang H; Li Y, 2019, 'Liquid biopsy in ovarian cancer: Recent advances in circulating extracellular vesicle detection for early diagnosis and monitoring progression', Theranostics, vol. 9, pp. 4130 - 4140, http://dx.doi.org/10.7150/thno.34692

Ni J; Cozzi P; Beretov J; Duan W; Bucci J; Graham P; Li Y, 2018, 'Epithelial cell adhesion molecule (EpCAM) is involved in prostate cancer chemotherapy/radiotherapy response in vivo', BMC Cancer, vol. 18, pp. 1092, http://dx.doi.org/10.1186/s12885-018-5010-5

Bai X; Ni J; Beretov J; Graham P; Li Y, 2018, 'Cancer stem cell in breast cancer therapeutic resistance', Cancer Treatment Reviews, vol. 69, pp. 152 - 163, http://dx.doi.org/10.1016/j.ctrv.2018.07.004

Wu D; Ni J; Beretov J; Cozzi P; Willcox M; Wasinger V; Walsh B; Graham P; Li Y, 2017, 'Urinary biomarkers in prostate cancer detection and monitoring progression', Critical Reviews in Oncology/Hematology, vol. 118, pp. 15 - 26, http://dx.doi.org/10.1016/j.critrevonc.2017.08.002

Chang L; Ni J; Beretov J; Wasinger VC; Hao J; Bucci J; Malouf D; Gillatt D; Graham PH; Li Y, 2017, 'Identification of protein biomarkers and signaling pathways associated with prostate cancer radioresistance using label-free LC-MS/MS proteomic approach', Scientific Reports, vol. 7, http://dx.doi.org/10.1038/srep41834

Ni J; Bucci J; Chang L; Malouf D; Graham P; Li Y, 2017, 'Targeting microRNAs in prostate cancer radiotherapy', Theranostics, vol. 7, pp. 3243 - 3259, http://dx.doi.org/10.7150/thno.19934

Deng J; Wang L; Ni J; Beretov J; Wasinger V; Wu D; Duan W; Graham P; Li Y, 2016, 'Proteomics discovery of chemoresistant biomarkers for ovarian cancer therapy', Expert Review of Proteomics, vol. 13, pp. 905 - 915, http://dx.doi.org/10.1080/14789450.2016.1233065

Ni J; Cozzi P; Hung T; Hao J; Graham PH; Li Y, 2016, 'Monitoring Prostate Tumor Growth in an Orthotopic Mouse Model Using Three-Dimensional Ultrasound Imaging Technique', Translational Oncology, vol. 9, pp. 41 - 45, http://dx.doi.org/10.1016/j.tranon.2015.11.011

Chang L; Graham P; Hao J; Ni J; Deng J; Bucci J; Malouf D; Gillatt D; Li Y, 2016, 'Cancer stem cells and signaling pathways in radioresistance', Oncotarget, vol. 7, pp. 11002 - 11017, http://dx.doi.org/10.18632/oncotarget.6760

Hao J; Graham P; Chang L; Ni J; Wasinger V; Beretov J; Deng J; Duan W; Bucci J; Malouf D; Gillatt D; Li Y, 2016, 'Proteomic identification of the lactate dehydrogenase A in a radioresistant prostate cancer xenograft mouse model for improving radiotherapy', Oncotarget, vol. 7, pp. 74269 - 74285, http://dx.doi.org/10.18632/oncotarget.12368

Deng J; Wang L; Chen H; Hao J; Ni J; Chang L; Duan W; Graham P; Li Y, 2016, 'Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer', Oncotarget, vol. 7, pp. 55771 - 55788, http://dx.doi.org/10.18632/oncotarget.9908

Deng J; Wang L; Chen H; Hao J; Ni J; Chang L; Duan W; Graham P; Li Y, 2016, 'Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer', Oncotarget, vol. 7, pp. 55518 - 55528, http://dx.doi.org/10.18632/oncotarget.10833

Chang L; Graham PH; Ni J; Hao J; Bucci J; Cozzi PJ; Li Y, 2015, 'Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance', Critical Reviews in Oncology/Hematology, vol. 96, pp. 507 - 517, http://dx.doi.org/10.1016/j.critrevonc.2015.07.005

Chang L; Graham P; Hao J; Bucci J; Malouf D; Gillatt D; Li Y, 2015, 'Proteomics discovery of radioresistant cancer biomarkers for radiotherapy', Cancer Letters, vol. 369, pp. 289 - 297, http://dx.doi.org/10.1016/j.canlet.2015.09.013

Lei C; Wasinger V; Graham P; Hao J; Ni J; Beretov J; Bucci J; Cozzi P; Kearsley J; Li Y, 2014, 'THE USE OF LABEL-FREE LC-MS/MS APPROACH TO IDENTIFY SIGNALING PATHWAYS ASSOCIATED WITH PROSTATE CANCER RADIORESISTANCE', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, vol. 10, pp. 130 - 130, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000345350900164&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Ni J; Cozzi P; Hao J; Duan W; Graham P; Kearsley J; Li Y, 2014, 'Cancer stem cells in prostate cancer chemoresistance', Current Cancer Drug Targets, vol. 14, pp. 225 - 240, http://dx.doi.org/10.2174/1568009614666140328152459

Chang L; Graham PH; Hao J; Ni J; Bucci J; Cozzi PJ; Kearsley JH; Li Y, 2014, 'PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways', Cell Death and Disease, vol. 5, http://dx.doi.org/10.1038/cddis.2014.415

Ni J; Cozzi PJ; Hao JL; Beretov J; Chang L; Duan W; Shigdar S; Delprado WJ; Graham PH; Bucci J; Kearsley JH; Li Y, 2014, 'CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance', The Prostate, vol. 74, pp. 602 - 617, http://dx.doi.org/10.1002/pros.22775

Deng J; Wang L; Chen H; Li L; Ma Y; Ni J; Li Y, 2013, 'The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression', Cancer and Metastasis Reviews, vol. 32, pp. 535 - 551, http://dx.doi.org/10.1007/s10555-013-9423-y

Ni J; Cozzi P; Hao J; Beretov J; Chang L; Duan W; Shigdar S; Delprado W; Graham P; Bucci J; Kearsley J; Li Y, 2013, 'Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway', International Journal of Biochemistry and Cell Biology, vol. 45, pp. 2736 - 2748, http://dx.doi.org/10.1016/j.biocel.2013.09.008

Chang L; Graham PH; Hao J; Ni J; Bucci J; Cozzi PJ; Kearsley JH; Li Y, 2013, 'Acquisition of epithelialmesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance', Cell Death and Disease, vol. 4, http://dx.doi.org/10.1038/cddis.2013.407

Xiao W; Graham PH; Hao J; Chang L; Ni J; Power CA; Dong Q; Kearsley JH; Li Y, 2013, 'Combination Therapy with the Histone Deacetylase Inhibitor LBH589 and Radiation Is an Effective Regimen for Prostate Cancer Cells', PLoS ONE, vol. 8, http://dx.doi.org/10.1371/journal.pone.0074253

Hao J; Ni J; Cozzi PJ; Graham PH; Bucci J; Kearsley J; Li Y, 2013, 'The CD44 Isoforms in Prostate Cancer Metastasis and progression', World Journal of Cancer Research, vol. 1, pp. 3 - 14, http://dx.doi.org/10.1166/wjcr.2013.1009

Conference Papers

Ni J; Cozzi P; Beretov J; Deng J; Bucci J; Graham P; Li Y, 2017, 'Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer progression and chemo/radio-resistance in vitro and in vivo', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Washington, DC, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), Washington, DC, 01 April 2017 - 05 April 2017, http://dx.doi.org/10.1158/1538-7445.AM2017-2833

Ni J; Cozzi P; Hao J; Beretov J; Chang L; Duan W; Delprado W; Graham P; Bucci J; Kearsley J; Li Y, 2014, 'CD44 isoform variant 6 is associated with prostate cancer progression, metastasis and chemo-/radio-resistance via PI3K/Akt/mTOR and Wnt/beta-catenin signaling pathways in vitro', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, San Diego, CA, presented at 105th Annual Meeting of the American-Association-for-Cancer-Research (AACR), San Diego, CA, 05 April 2014 - 09 April 2014, http://dx.doi.org/10.1158/1538-7445.AM2014-4005

Conference Presentations

Ni K, 2015, 'Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer chemo-/radio-resistance in cell lines in vitro and in animal models in vivo.', presented at 2nd Prostate Cancer World Congress, Cairns, QLD, Australia, 17 August 2015 - 21 August 2015

Chang L; Peter G; Hao J; Ni J; Bucci J; Cozzi PJ; Kearsley J; Li Y; Hao J, 2012, 'Epithelial mesenchymal transition (EMT) is involved in the prostate cancer radiation resistance.', Vol. 8, pp. 333 - 333, presented at IPOS 14th World Congress and COSA's 39th Annual Scientific Meeting, Brisbane, Australia, 13 November 2012 - 15 November 2012, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000310544400351&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Ni K, 2012, 'EpCAM (CD326) and CD44 variants are biomarkers associated with prostate cancer metastasis and progression.', presented at The St George & Sutherland Medical Research Symposium, 11 October 2012 - 11 October 2012

Conference Abstracts

Ni J; Cozzi P; Beretov J; Bucci J; Graham P; Li Y, 2017, 'Studying CD44 variant 6 (CD44v6) in prostate cancer progression and chemo-/radio-resistance using in vivo mouse models', in Annals of Oncology, OXFORD UNIV PRESS, Singapore, SINGAPORE, Vol. 28, pp. x78 - x79, presented at ESMO Asia Congress, Singapore, SINGAPORE, 17 November 2017 - 19 November 2017, http://dx.doi.org/10.1093/annonc/mdx662.006

Hao J; Graham P; Chang L; Ni J; Beretov J; Deng J; Bucci J; Cozzi P; Li Y, 2015, 'Combination of LBH589 and radiotherapy overcomes radioresistance in radioresistant prostate cancer cells in vitro and animal models in vivo', in BJU INTERNATIONAL, WILEY-BLACKWELL, Cairns, AUSTRALIA, Vol. 116, pp. 33 - 34, presented at 2nd Prostate Cancer World Congress (PCWC), Cairns, AUSTRALIA, 17 August 2015 - 21 August 2015, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000359254200095&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Ni J; Cozzi P; Hao J; Beretov J; Chang L; Deng J; Duan W; Graham P; Bucci J; Li Y, 2015, 'Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer chemo-/radio-resistance in cell lines in vitro and in animal models in vivo', in BJU INTERNATIONAL, WILEY-BLACKWELL, Cairns, AUSTRALIA, Vol. 116, pp. 31 - 31, presented at 2nd Prostate Cancer World Congress (PCWC), Cairns, AUSTRALIA, 17 August 2015 - 21 August 2015, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000359254200087&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hao J; Graham PH; Chang L; Ni J; Wasinger V; Beretov J; Bucci J; Cozzi P; Li Y, 2015, 'Identification of lactate dehydrogenase A (LDHA) as a potential therapeutic target for prostate cancer radiotherapy', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Philadelphia, PA, Vol. 75, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), Philadelphia, PA, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-2001

Ni K, 2014, 'CD44 isoform variant 6 is associated with prostate cancer progression, metastasis and chemo-/radio-resistance via PI3K/Akt/mTOR and Wnt/β-catenin signalling pathways in vitro.', in CD44 isoform variant 6 is associated with prostate cancer progression, metastasis and chemo-/radio-resistance via PI3K/Akt/mTOR and Wnt/β-catenin signalling pathways in vitro., AACR 2014, presented at AACR 2014

Ni K, 2013, 'CD44 variant 6 is a biomarker associated with prostate cancer metastasis and progression.', in CD44 variant 6 is a biomarker associated with prostate cancer metastasis and progression., The St George & Sutherland Medical Research Symposium, presented at The St George & Sutherland Medical Research Symposium

Ni K, 2013, 'CD44 variant 6 is a biomarker associated with prostate cancer metastasis and progression.', in CD44 variant 6 is a biomarker associated with prostate cancer metastasis and progression., LOWY cancer symposium, presented at LOWY cancer symposium

Ni K, 2012, 'Over-expression of EpCAM (CD326) and CD44 variants in human prostate cancer cells are potential therapeutic targets for targeted therapy.', in Over-expression of EpCAM (CD326) and CD44 variants in human prostate cancer cells are potential therapeutic targets for targeted therapy., 13th Australasian Prostate Cancer Conference, presented at 13th Australasian Prostate Cancer Conference


Back to profile page